Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales: Huiberts, Anne J, de Gier, Brechje, Hoeve, Christina E, de Melker, Hester E, Hahné, Susan JM, den Hartog, Gerco, van de Wijgert, Janneke HHM, van den Hof, Susan, Knol, Mirjam J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936593/
https://www.ncbi.nlm.nih.gov/pubmed/36795500
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2300087
_version_ 1784890263466934272
author Huiberts, Anne J
de Gier, Brechje
Hoeve, Christina E
de Melker, Hester E
Hahné, Susan JM
den Hartog, Gerco
van de Wijgert, Janneke HHM
van den Hof, Susan
Knol, Mirjam J
author_facet Huiberts, Anne J
de Gier, Brechje
Hoeve, Christina E
de Melker, Hester E
Hahné, Susan JM
den Hartog, Gerco
van de Wijgert, Janneke HHM
van den Hof, Susan
Knol, Mirjam J
author_sort Huiberts, Anne J
collection PubMed
description We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18–59-year-olds and 14% in 60–85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.
format Online
Article
Text
id pubmed-9936593
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-99365932023-02-18 Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022 Huiberts, Anne J de Gier, Brechje Hoeve, Christina E de Melker, Hester E Hahné, Susan JM den Hartog, Gerco van de Wijgert, Janneke HHM van den Hof, Susan Knol, Mirjam J Euro Surveill Rapid Communication We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18–59-year-olds and 14% in 60–85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection. European Centre for Disease Prevention and Control (ECDC) 2023-02-16 /pmc/articles/PMC9936593/ /pubmed/36795500 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2300087 Text en This article is copyright of the authors or their affiliated institutions, 2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Huiberts, Anne J
de Gier, Brechje
Hoeve, Christina E
de Melker, Hester E
Hahné, Susan JM
den Hartog, Gerco
van de Wijgert, Janneke HHM
van den Hof, Susan
Knol, Mirjam J
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
title Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
title_full Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
title_fullStr Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
title_full_unstemmed Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
title_short Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
title_sort effectiveness of bivalent mrna booster vaccination against sars-cov-2 omicron infection, the netherlands, september to december 2022
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936593/
https://www.ncbi.nlm.nih.gov/pubmed/36795500
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2300087
work_keys_str_mv AT huibertsannej effectivenessofbivalentmrnaboostervaccinationagainstsarscov2omicroninfectionthenetherlandsseptembertodecember2022
AT degierbrechje effectivenessofbivalentmrnaboostervaccinationagainstsarscov2omicroninfectionthenetherlandsseptembertodecember2022
AT hoevechristinae effectivenessofbivalentmrnaboostervaccinationagainstsarscov2omicroninfectionthenetherlandsseptembertodecember2022
AT demelkerhestere effectivenessofbivalentmrnaboostervaccinationagainstsarscov2omicroninfectionthenetherlandsseptembertodecember2022
AT hahnesusanjm effectivenessofbivalentmrnaboostervaccinationagainstsarscov2omicroninfectionthenetherlandsseptembertodecember2022
AT denhartoggerco effectivenessofbivalentmrnaboostervaccinationagainstsarscov2omicroninfectionthenetherlandsseptembertodecember2022
AT vandewijgertjannekehhm effectivenessofbivalentmrnaboostervaccinationagainstsarscov2omicroninfectionthenetherlandsseptembertodecember2022
AT vandenhofsusan effectivenessofbivalentmrnaboostervaccinationagainstsarscov2omicroninfectionthenetherlandsseptembertodecember2022
AT knolmirjamj effectivenessofbivalentmrnaboostervaccinationagainstsarscov2omicroninfectionthenetherlandsseptembertodecember2022

Ejemplares similares